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OBJECTIVES: Limited information exists on utility in CRPC patients, especially in
mCRPC patients who progress after first line therapy. This study is to describe
correlates of utility assessments in patients with mCRPC who have progressed
during or after docetaxel first-line therapy. METHODS: An observational study of
mCRPC patients progressing during or after the first-line docetaxel therapy was
performed in US, France, Germany and UK. Patient characteristics, first-line treat-
ment details and quality of life using a generic EQ-5D questionnaire were evaluated
at the time of second line treatment decision. Descriptive analyses and multivari-
ate analysis for EQ-5D utility index are presented. RESULTS: Eighty-two patients
were recruited in the study and 74 patients had an evaluable EQ-5D questionnaire.
In this subset the median age was 72 years and 81% had a good ECOG performance
status (ECOG-PS score 0 or 1). The mean ( SD) utility index was 0.63 ( 0.26).
Relationship between utility index and potential correlates was analysed using
univariate regressions. Age, ECOG-PS and time since diagnosis were related with
the utility score, but stage at diagnosis, time between last dose of treatment and
progression, total number of docetaxel cycles and response to first line treatment were
not. After multivariate adjustment for these correlates and accounting for country
variation, ECOG-PS (0-1 versus 2-3) was the strongest predictor of utility index
(p.0001), with a strong utility increment of 0.38 for ECOG-PS 0-1 patients. Age (18-64,
65-74, 3 75 years) and time since diagnosis (2, 2-4, 4-8,8 years) were not statistically
significant (p0.127 and 0.072, respectively). There was no difference between coun-
tries (p0.329). CONCLUSIONS: In metastatic prostate cancer patients who have
reached castration-resistant stage and progressed after first-line docetaxel,
ECOG-PS is the strongest correlate of utility score measured by EQ-5D. This finding
appears equally applicable across several European countries and US.
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OBJECTIVES: To develop a mapping algorithm for a conversion of the EORTC QLQ-
C30 and EORTC QLQ BR-23 into the EQ-5D derived utilities in metastatic breast
cancer (MBC) patients.METHODS:We enrolled 199 patients with MBC from the four
leading Korean hospitals in 2009. EQ-5D utility, cancer-specific (QLQ-C30) and
breast cancer-specific quality of life data (QLQ-BR23), and selected clinical and
demographic information were collected from the study participants. Ordinary
least squares regression models were used to model the EQ-5D using QLQ-C30 and
QLQ-BR23 scale scores. To select the best model specification, six different sets of
explanatory variables were compared. RESULTS: Regression analysis with the
multi-item scale scores of QLQ-C30 was the best-performing model, explaining for
48.7% of the observed EQ-5D variation. Its mean absolute error between the ob-
served and predicted EQ-5D utilities (0.092) and relative prediction error (2.784%)
was among the smallest. Also, this mapping model showed the least systematic
errors according to disease severity. CONCLUSIONS: The mapping algorithms de-
veloped have good predictive validity and therefore they enable researchers to
translate cancer-specific health-related quality-of-life measures to the preference-
adjusted health status of MBC patients.
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OBJECTIVES: Skeletal related events (SREs) are a major cause of morbidity for cas-
tration resistant prostate cancer (CRPC) patients with bone metastases. SREs can
have a debilitating effect on patient’s quality of life (QoL), although severity de-
pends on the type of SRE. The purpose of this study is to determine what data are
available on utility weights by SRE type for use in a cost-utility analysis of CRPC.
METHODS: A systematic literature review of PubMed was performed to identify
data on SRE utilities. The search was limited to the past 10 years and to metastatic
cancer and bone neoplasms. RESULTS: The search yielded 82 articles, of these 19
contained SRE and utility information only 8 of which reported utility weights. One
article reported a utility decrement for hip fractures (0.03) in CRPC. Another re-
ported utility decrements for pathologic fractures (0.13) and radiation to bone (0.07)
in metastatic prostate cancer (mPCa). Two articles contained utility data differen-
tiated per SRE for non-small-cell lung carcinoma (NSCLC) and advanced renal cell
carcinoma (aRCC). These decrements were calculated using a multiplier per SRE
derived from an earlier study in metastatic breast cancer (mBCa) and ranged from
0.05 for vertebral fractures to 0.50-0.61 for spinal cord compression. The other 4
articles only reported the overall utility, but did not specify per type of SRE.
CONCLUSIONS: To accurately model the impact of SREs on CRPC, QoL utility
weights should be assigned to each SRE type to account for their varying severity.
This study found only one article with a utility weight for a specific SRE in CRPC and
one for mPCa. However, the use of SRE utility weights derived from a mBCa study
for measuring SRE decrements in NSCLC and aRCC suggest SRE utility weights
derived from other cancers may be acceptable for a CRPC cost-utility analysis.
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OBJECTIVES: This study aims to perform a systematic expert evaluation of the
measurement properties of specific health-related quality of life instruments for
prostate cancer. METHODS: We conducted a systematic literature search to iden-
tify articles about specific health-related quality of life instruments developed for
prostate cancer. Secondly, titles and abstracts were reviewed independently by two
experts and, in case of discrepancies, by a third expert to filter the information.
Thirdly, for every instrument identified, two experts reviewed the articles about
measurement properties and applied the EMPRO tool (Evaluating the Measurement
of Patient-Reported Outcomes), which was specifically designed for a standardized
evaluation of measurement properties of PRO instruments regarding: conceptual
and measurement model, reliability, validity and responsiveness among other.
Scores are transformed to a scale from 0 to 100. RESULTS: Ten specific question-
naires were indentified with great variability regarding available information on
measurement properties (between 2 and 13 articles): DALE questionnaire (2), ES-
CAP_CDV (2), TALCOTT questionnaire (2), PCQoL (3), EORTC QLQ PR-25 (3), PORPUS
(3), PROSQOLI (4), EPIC (7), FACT-P (11) and UCLA-PCI (13). Only 5 out of 10 ques-
tionnaires provided full information regarding their measurement properties. Re-
garding their conceptual and measurement model, EPIC demonstrated the highest
score (90), followed by UCLA-PCI, PROSQOLI, Talcott questionnaire, PCQoL,
EORTC PR25, and PORPUS (50). Only three questionnaires presented high reliabil-
ity scores (EPIC and PCQoL 80, UCLA-PCI 50). UCLA-PCI showed the highest
scores for validity (80), followed by PORPUS and PCQoL (70), PROSQOLI and EPIC
(50). Highest responsiveness scores were observed for PCQoL (100), EPIC and POR-
PUS (80), and PROSQOLI (70).CONCLUSIONS: In this systematic evaluation, only
2 out of 10 questionnaires provided information supporting their conceptual and
measurement model, as well as good reliability, validity and responsiveness: EPIC
and PCQoL. All instruments have a psychometric design except PORPUS, which
was designed to perform cost-utility analysis.
PCN132
A DEVELOPMENT OF QUALITY INDICATORS FOR EVALUATING HOME
PALLIATIVE CARE AND THEIR RELATION WITH BEREAVED FAMILY
SATISFACTION
Saito S1, Shimozuma K2, Yamaguchi M3, Ueda K4
1Okayama University, Okayama, Okayama, Japan, 2Ritsumeikan University, Kusatsu, Shiga,
Japan, 3Okayama Prefectural University, Soja, Okayama, Japan, 4Japan Red Cross Hiroshima
College of Nursing, Hatsukaichi, Hiroshima, Japan
OBJECTIVES: : To develop QI (Quality Indicator) specialized for evaluating domicil-
iary palliative care and to explore the relationship of this QI with family satisfaction
as a typical outcome of palliative care service at home. METHODS: A modified
Delphi method was adopted to select potential QIs and rate the appropriateness
and feasibility of them by multi-professional specialists engaged at home palliative
care. A retrospective study on the medical records to examine relation between the
developed QIs and FAMCARE (score of family satisfaction) was conducted on 44
patients with cancer who received home palliative care service between 2001 and
2008 at a regional clinic in Japan. RESULTS: Twelve indicators were selected and
included some items concerning long-term care insurance, surroundings and re-
habilitation. A number compatible with the QIs was 7.5  3.4 and found to have
weak relationship with length of the home care (correlation coefficient 0. 298
(p0.05)). It also showed correlation with FAMCARE average scores (correlation
coefficient 0. 431 (p0.04)). CONCLUSIONS: These QIs seem to be useful for moni-
toring and evaluating home palliative care but have some problems such as mix-
ture of indicators for evaluating end-of-life care and care in the stable stage. The
number of QIs documented on the charts was related with the FAMCARE score,
which might be affected by the period of the home care.
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OBJECTIVES: Integrative therapy may focus on the synergic effect of complemen-
tary therapies to increase effectiveness of conventional treatment. Korean cancer
patients may expect better care with integrative cancer therapy of combining con-
ventional western treatment with traditional Korean medicine (TKM), and eventu-
ally determine their satisfaction with the outcomes of treatment. The objective of
this study was to investigate patients’ expectation and satisfaction with the inte-
grative cancer therapy.METHODS:A total of 102 cancer patients were participated.
Due to the specialty of Integrative Cancer Center (ICC) for those who received only
western treatment received care elsewhere. Based on clinical decision at ICC, pa-
tients received either integrative treatment with combining conventional treat-
ment with TKM (n55) or TKM only (n43). At ICC, Rhus verniciflua Stokes Extract
which is described in the literature was used as TKM. We use Korean translation of
Cancer Therapy Satisfaction Questionnaire (CTSQ) to measure patients’ expecta-
tion and satisfaction. RESULTS: Mean age was 51.9 and most were stage 4 (74.4%).
In the integrative therapy group, mean scores of Expectations of Therapy (ET),
Feelings about Side Effects (FSE), Satisfaction with Therapy (SWT) domains were
80.7/15.0, 74.9/23.5, and 73.7/14.6, respectively, whereas in the TKM
group, mean scores of ET, FSE, SWT were 80.8/16.8, 87.5/19.3, and 78.1/
14.5, respectively. Only FSE was statistically different between the two groups
(p.0054). Similar results were seen in stage 4 patients. Cronbach’s alpha of this
Korean CTSQ domains were acceptable (0.74-0.86). CONCLUSIONS: Previously
treated cancer patients in particular, eventually seek additional care with integra-
tive cancer therapy. Their expectation about integrative cancer therapy, however,
was not much different from traditional medicine. This may due to hard experi-
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